联环药业,600513,收入构成,报告日期,2020-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 针剂,18382,2707,15675,85.27%,21.01% 原料药,23586,15310,8276,35.09%,11.09% 其他(补充),1844,1476,368,19.94%,0.49% 其他,24159,19111,5048,20.9%,6.77% 片剂,70632,25379,45254,64.07%,60.64% 联环药业,600513,收入构成,报告日期,2019-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 针剂,22302,2182,20120,90.21%,25.91% 片剂,70975,24231,46744,65.86%,60.19% 其他(补充),286,212,74,25.99%,0.1% 其他,18239,15308,2931,16.07%,3.77% 原料药,17230,9436,7795,45.24%,10.04% 联环药业,600513,收入构成,报告日期,2018-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,4510,2616,1894,42%,2.71% 原料药,14964,8162,6802,45.45%,9.73% 针剂,31471,6705,24766,78.7%,35.42% 其他(补充),84,62,23,26.96%,0.03% 片剂,50895,14463,36432,71.58%,52.11% 联环药业,600513,收入构成,报告日期,2017-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 针剂,14555,2734,11821,81.22%,24.89% 其他,1146,917,229,19.98%,0.48% 其他(补充),370,350,20,5.43%,0.04% 片剂,41972,11202,30770,73.31%,64.79% 原料药,10867,6216,4651,42.8%,9.79% 联环药业,600513,收入构成,报告日期,2016-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),213,135,79,36.82%,0.22% 其他,251,212,40,15.77%,0.11% 针剂,7550,3676,3874,51.31%,10.95% 片剂,39104,12864,26240,67.1%,74.17% 原料药,13368,8222,5146,38.5%,14.55% 联环药业,600513,收入构成,报告日期,2016-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),398,261,137,34.41%,0.83% 其他,71,59,12,16.52%,0.07% 针剂,3089,1850,1239,40.11%,7.53% 片剂,19541,7133,12409,63.5%,75.43% 原料药,7984,5330,2654,33.24%,16.13% 联环药业,600513,收入构成,报告日期,2015-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),254,89,165,64.79%,0.45% 其他,248,203,45,18.27%,0.12% 针剂,10372,3292,7081,68.27%,19.35% 片剂,38645,14499,24145,62.48%,66% 原料药,14724,9575,5149,34.97%,14.07% 联环药业,600513,收入构成,报告日期,2015-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),154,174,-19,-12.46%,-0.11% 片剂,19564,7685,11880,60.72%,66.81% 其他,59,55,4,6.86%,0.02% 原料药,8153,5504,2649,32.49%,14.9% 针剂,4902,1634,3268,66.66%,18.38% 联环药业,600513,收入构成,报告日期,2014-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 片剂,37355,14915,22440,60.07%,64.53% 其他(补充),223,276,-53,-23.95%,-0.15% 原料药,16653,12068,4585,27.53%,13.18% 针剂,12221,4419,7802,63.84%,22.44% 联环药业,600513,收入构成,报告日期,2014-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),128,272,-144,-112.06%,-0.88% 其他,139,130,9,6.41%,0.05% 针剂,5851,2019,3832,65.49%,23.54% 片剂,18391,7831,10560,57.42%,64.87% 原料药,9124,7103,2021,22.15%,12.41% 联环药业,600513,收入构成,报告日期,2013-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),984,1063,-79,-8.07%,-0.27% 其他,310,291,19,6%,0.06% 针剂,10150,3667,6483,63.87%,22.44% 片剂,34521,15443,19078,55.27%,66.04% 原料药,16366,12976,3390,20.71%,11.73% 联环药业,600513,收入构成,报告日期,2013-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其中:其他,82,98,-16,-19.68%,-0.07% 其中:片剂,16353,7406,8947,54.71%,40.08% 片剂等,16435,7504,8931,54.34%,40.01% 其他(补充),261,713,-452,-172.83%,-2.02% 针剂,4626,1286,3340,72.21%,14.97% 原料药,7336,5766,1570,21.4%,7.03% 联环药业,600513,收入构成,报告日期,2012-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,161,143,17,10.86%,0.1% 片剂等,30835,13510,17326,56.19%,97.76% 原料药,717,543,173,24.18%,0.98% 其他(补充),823,617,206,25.01%,1.16% 联环药业,600513,收入构成,报告日期,2012-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),322,217,105,32.55%,1.25% 原料药,2,2,-0,-1.48%,-0% 片剂等,15015,6775,8240,54.88%,98.75% 联环药业,600513,收入构成,报告日期,2011-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),737,519,218,29.56%,1.35% 其他,26,16,10,38.8%,0.06% 片剂等,30974,15197,15777,50.94%,97.87% 原料药,684,568,116,16.95%,0.72% 联环药业,600513,收入构成,报告日期,2011-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),362,259,103,28.33%,1.39% 片剂等,13996,6706,7290,52.08%,98.5% 原料药,15,7,9,56.73%,0.12% 联环药业,600513,收入构成,报告日期,2010-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,34,16,18,53.28%,0.13% 原料药,982,705,276,28.16%,1.98% 片剂等,27165,13528,13637,50.2%,97.88% 联环药业,600513,收入构成,报告日期,2010-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 片剂等,13713,7268,6445,47%,99.93% 原料药,25,21,5,18.21%,0.07% 联环药业,600513,收入构成,报告日期,2009-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 片剂等,24405,12346,12059,49.41%,98.6% 原料药,688,517,172,24.92%,1.4% 联环药业,600513,收入构成,报告日期,2009-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 片剂,11383,5683,5701,50.08%,100.4% 原料药,31,54,-23,-74.54%,-0.4% 联环药业,600513,收入构成,报告日期,2008-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 片剂,20976,10463,10513,50.12%,99.32% 原料药,800,727,72,9.03%,0.68% 联环药业,600513,收入构成,报告日期,2008-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 片剂,10433,5236,5197,49.81%,101.2% 原料药,117,178,-61,-52.68%,-1.2% 联环药业,600513,收入构成,报告日期,2007-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 泌尿外科用药,2210,814,1396,63.17%,19.31% 心血管药物,4261,1819,2442,57.32%,33.78% 抗过敏药物,5538,2145,3393,61.26%,46.92% 联环药业,600513,收入构成,报告日期,2007-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 片剂,9304,4948,4356,46.82%,100.43% 原料药,55,73,-19,-34.13%,-0.43% 联环药业,600513,收入构成,报告日期,2006-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 片剂,15239,7395,7844,51.47%,98.65% 原料药,1385,1277,108,7.78%,1.35% 联环药业,600513,收入构成,报告日期,2006-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 泌尿外科用药,393,209,185,46.93%,19.34% 心血管类药物,796,444,352,44.21%,36.86% 抗过敏类药物,1547,1129,418,27.03%,43.81% 联环药业,600513,收入构成,报告日期,2006-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新药,4913,1381,3532,71.9%,94.84% 片剂,2110,1913,196,9.31%,5.27% 原料药,441,445,-4,-0.92%,-0.11% 联环药业,600513,收入构成,报告日期,2006-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 泌尿外科用药,361,185,176,48.77%,16.68% 心血管药,996,491,505,50.69%,47.85% 抗过敏药,786,412,374,47.63%,35.47% 联环药业,600513,收入构成,报告日期,2005-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新药,9853,3556,6297,63.91%,84.3% 片剂,4662,3569,1093,23.44%,14.63% 原料药,2784,2704,80,2.87%,1.07% 联环药业,600513,收入构成,报告日期,2005-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 甾体激素类原料药,1621,1597,24,1.47%,1.1% 泌尿外科用药,767,404,362,47.26%,16.7% 心血管类药,2358,1383,975,41.36%,44.95% 抗过敏类药,2847,2039,808,28.39%,37.26% 联环药业,600513,收入构成,报告日期,2005-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 原料药,1847,0,1847,100%,20.01% 新药,4376,0,4376,100%,47.42% 片剂,3006,0,3006,100%,32.57% 联环药业,600513,收入构成,报告日期,2005-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 征之,173,0,173,100%,10.54% 爱普列特,224,0,224,100%,13.64% 联环尔定,601,0,601,100%,36.6% 敏迪,644,0,644,100%,39.22% 联环药业,600513,收入构成,报告日期,2004-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 泌尿外科用药,823,0,823,100%,11.92% 心血管药,3608,0,3608,100%,52.23% 抗过敏药,2477,0,2477,100%,35.85% 联环药业,600513,收入构成,报告日期,2004-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 联环尔定,1429,0,1429,100%,32.72% 达那唑胶囊,500,0,500,100%,11.45% 爱普列特片,547,0,547,100%,12.52% 敏迪,1892,0,1892,100%,43.32% 联环药业,600513,收入构成,报告日期,2004-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 联环尔定,967,0,967,100%,37.04% 达那唑胶囊,320,0,320,100%,12.26% 爱普列特片,280,0,280,100%,10.72% 敏迪,1044,0,1044,100%,39.98% 联环药业,600513,收入构成,报告日期,2004-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 辛伐他汀片,210,-- ,-- ,--,0% 联环尔定片,424,0,424,100%,47.04% 敏迪(特非那丁片),478,0,478,100%,52.96% 联环药业,600513,收入构成,报告日期,2003-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 技术咨询,70,85,-15,-21.03%,-0.31% 新药,5719,2334,3385,59.19%,72.2% 片剂,1905,1038,867,45.52%,18.5% 原料药,3540,3089,451,12.74%,9.62% 联环药业,600513,收入构成,报告日期,2003-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 氢化可的松原料药,1540,0,1540,100%,32.08% 联环尔定片,583,0,583,100%,12.13% 非洛地平片,300,0,300,100%,6.26% 爱普列特片,771,0,771,100%,16.06% 敏迪(特非那丁片),1607,0,1607,100%,33.47% 联环药业,600513,收入构成,报告日期,2003-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 新药,2917,0,2917,100%,73.8% 片剂,361,0,361,100%,9.12% 原料药,675,0,675,100%,17.08%